Neuroendocrine Tumors (NETs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Neuroendocrine tumors, arising from neuroendocrine cells, are malignant growths. They are most frequently found in the gastrointestinal tract (48%), lungs (25%), and pancreas (9%). However, they can also develop in other organs like the breast, prostate, thymus, and skin. Neuroendocrine cells can produce hormones, such as serotonin, leading to symptoms like flushing and diarrhea. Additionally, they produce proteins like chromogranin A, which serve as biomarkers for NETs. Neuroendocrine tissues commonly express somatostatin receptors on their cell surfaces. Three clinicopathologic features—grade, differentiation, and stage—determine the biological behavior of NETs. NETs can either be discovered incidentally or suspected due to clinical symptoms. When NETs cause symptoms through hormone secretion, they are termed “functioning,” and those that do not produce active hormones are termed “nonfunctioning.” Both types present late with nonspecific symptoms, often leading to misdiagnoses. Diagnosing NETs involves pathology testing and integrated hormonal and diagnostic imaging to create a comprehensive diagnostic profile. The standard treatment for NETs involves complete tumor removal, with most localized NETs successfully treated through surgery alone. Several drugs, such as Lutathera (lutetium Lu 177 dotatate), Belzutifan, Streptozotocin, Afinitor (everolimus), Sutent (sunitinib), and Xermelo (telotristat), have received FDA approval for treating NETs.
• The overall incidence of NETs in the USA is 2.89 per 100,000 people annually.

Thelansis’s “Neuroendocrine Tumors (NETs) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Neuroendocrine Tumors (NETs) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Neuroendocrine Tumors (NETs) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Neuroendocrine Tumors (NETs) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Neuroendocrine Tumors (NETs) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Neuroendocrine Tumors (NETs), Neuroendocrine Tumors (NETs) market outlook, Neuroendocrine Tumors (NETs) competitive landscape, Neuroendocrine Tumors (NETs) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)